HYPERTENSION IN THE ACUTE MEDICAL ASSESSMENT UNIT IN ST. LUKE’S GENERAL HOSPITAL KILKENNY – ARE WE ADHERING TO GUIDELINES?

K Millar, C Crowley, P Cotter. St Luke’s Hospital, Kilkenny, Ireland

Background Hypertension is a common reason for GP referral to the Acute Medical Assessment Unit (AMAU) in St. Luke’s Hospital, Kilkenny (SLK). Hypertensive emergency requires urgent and aggressive blood pressure control to limit end-organ damage. Management of hypertension has been proven to reduce the incidence of cardiac events, cardiovascular death and stroke. The aims of this audit were: 1. To ascertain what percentage of patients referred with hypertension were diagnosed with hypertensive emergency. 2. To review whether or not patients referred with hypertension had had appropriate work up (with electrocardiogram and urine dipstick.) 3. To review what percentage of patients deemed not to have hypertensive emergency received unindicated stat doses of antihypertensives. 4. To assess what percentage of patients referred with hypertension were diagnosed with hypertensive emergency. Both were managed with oral antihypertensives. 83 patients (91%) were asked about symptoms of hypertension, 43 (48%) received a stat dose of an oral antihypertensive. 11 patients (12%) had their stage of hypertension updated. Of these, 8 (73%) were discharged on a statin for at least 4 weeks. Receiving a stable dose of a statin for at least 4 weeks.

Results 106 patients were referred to the AMAU by GPs with hypertension between January 2019 and January 2020. 91 patients were included in the study. 35 (38%) were male and 56 (62%) were female. The median age of patients was 60. 2 patients (2.2%) were diagnosed with hypertensive emergency. Both were managed with oral antihypertensives. 83 patients (91%) were asked about symptoms of hypertension, 86 patients (95%) had an ECG. Only 26 (29%) had a urine dipstick. Of the 89 patients deemed not to have hypertensive emergency, 43 (48%) received a stat dose of an oral antihypertensive. 11 patients (12%) had their stage of hypertension documented. Of these, 8 (73%) were discharged on an appropriate antihypertensive. 24 patients (27%) had stage 1 hypertension, 27 (30%) had stage 2 and 38 (43%) had stage 3. On discharge, 40 patients (45%) were discharged on dual/triple antihypertensive regimens (in accordance with ESC-ESH guidelines.)

Of the 89 patients discharged from the AMAU, 69 (78%) were booked for a 24 hour ABPM and 26 (29%) were referred for TTE.

Conclusions This audit highlights numerous areas for improvement in the management of patients presenting to the AMAU in SLK with hypertension. It revealed that almost half of patients deemed to have no evidence of malignant hypertension/end-organ damage requiring immediate blood pressure control received at least one stat dose of an anti-hypertensive. The staging and management of hypertension remains a confusing area for some NCHDs, evidenced by the fact that only 12% of patients had their hypertension staged during their review. Positively, almost 80% of patients who presented to the AMAU with hypertension were booked for an outpatient 24 hour ABPM, however only 29% were booked for a TTE. We aim to develop a proforma for managing patients presenting with hypertension and re-educate our staff on the investigation and management of hypertensive patients in order to closer align our practices with ESC-ESH guidelines.

RESIDUAL RISK IN CARDIAC REHAB: CAN WE REDUCE-IT MORE? ELIGIBILITY FOR ICOsapent ETHyl IN PATIENTS ATTENDING CARDIAC REHABILITATION

S Gaine, 1J Coughlan, 2V Muher, 3M Waters. 1St James’s Hospital, Dublin, Ireland; 2German Heart Centre, Munich, Germany; 3Tallaght University Hospital, Tallaght, Dublin, Ireland

Introduction Patients with elevated triglycerides (TG) are at increased risk for ischemic events despite statin therapy and controlled low-density lipoprotein cholesterol (LDL-C). The REDUCE IT trial showed that a highly purified Eicosapentae-noic acid (EPA) ester, Icosapent Ethyl or Ethyl Eicosapentaenoic acid (E-EPA), reduces the risk of ischemic events and cardiovascular (CV) death in patients with elevated TG levels despite statin therapy. The NNT for the first occurrence of major adverse cardiac events for the five-point primary composite endpoint was 21. E-EPA is also a dominant strategy from a cost-effectiveness perspective in the study. Thus, the 2019 ESC/EAS guidelines recommend E-EPA for patients with persistently raised TGs despite treatment with a statin. Our aim was to assess the proportion of patients attending cardiac rehabilitation who may benefit from E-EPA therapy as per REDUCE-IT trial criteria and the 2019 ESC/EAS guidelines.

Methods We prospectively collected data on all cardiac rehabilitation patients in our centre in 2018/2019. We then performed a hierarchial analysis of these patients to determine the percentage of patients post MI/CABG that would meet criteria for E-EPA as per REDUCE-IT trial criteria and ESC/EAS guidelines.

The REDUCE IT trial criteria were:

- ≥45 years and established ASCVD
- 50 years with DM and at least one other CV RF
- Fasting TG level of 1.69 to 5.63 mmol/L
- LDL–C level of 1.06 to 2.59 mmol/L
- Receiving a stable dose of a statin for at least 4 weeks

The initial trial protocol enrolled patients with a TG level as low as 1.52 mmol/L to account for the ~10% variability in TG levels. This protocol was amended and changed the lower level for TG to 2.26 mmol/L. We analysed patients as per both protocols.

Abstracts